Jeff Jones
Stock Analyst at Oppenheimer
(1.81)
# 3,340
Out of 5,043 analysts
94
Total ratings
28.24%
Success rate
-5.07%
Average return
Main Sectors:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VTYX Ventyx Biosciences | Maintains: Outperform | $9 → $14 | $7.30 | +91.78% | 11 | Oct 27, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $53 → $63 | $61.48 | +2.47% | 6 | Oct 1, 2025 | |
| PTHS Pelthos Therapeutics | Initiates: Outperform | $50 | $31.36 | +59.44% | 1 | Sep 2, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Outperform | $10 → $25 | $3.13 | +700.00% | 9 | Aug 27, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Outperform | $56 → $53 | $17.44 | +203.90% | 10 | Aug 6, 2025 | |
| AVBP ArriVent BioPharma | Maintains: Outperform | $39 → $44 | $19.85 | +121.66% | 3 | Jun 24, 2025 | |
| ALMS Alumis | Maintains: Outperform | $26 → $25 | $4.83 | +417.60% | 3 | May 15, 2025 | |
| ZURA Zura Bio | Maintains: Outperform | $19 → $17 | $3.86 | +340.41% | 4 | May 9, 2025 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $15 → $17 | $7.70 | +120.78% | 5 | May 9, 2025 | |
| IMCR Immunocore Holdings | Maintains: Outperform | $85 → $86 | $33.99 | +153.02% | 2 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $18 | $7.44 | +141.94% | 4 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.52 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $16 | $2.94 | +444.22% | 7 | Nov 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $1.79 | +2,421.01% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $17.11 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.28 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $6.03 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.51 | +893.38% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $0.48 | +15,515.24% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,600 → $1,100 | $6.63 | +16,491.25% | 2 | Nov 17, 2022 |
Ventyx Biosciences
Oct 27, 2025
Maintains: Outperform
Price Target: $9 → $14
Current: $7.30
Upside: +91.78%
Kymera Therapeutics
Oct 1, 2025
Maintains: Outperform
Price Target: $53 → $63
Current: $61.48
Upside: +2.47%
Pelthos Therapeutics
Sep 2, 2025
Initiates: Outperform
Price Target: $50
Current: $31.36
Upside: +59.44%
Chemomab Therapeutics
Aug 27, 2025
Maintains: Outperform
Price Target: $10 → $25
Current: $3.13
Upside: +700.00%
Corbus Pharmaceuticals Holdings
Aug 6, 2025
Maintains: Outperform
Price Target: $56 → $53
Current: $17.44
Upside: +203.90%
ArriVent BioPharma
Jun 24, 2025
Maintains: Outperform
Price Target: $39 → $44
Current: $19.85
Upside: +121.66%
Alumis
May 15, 2025
Maintains: Outperform
Price Target: $26 → $25
Current: $4.83
Upside: +417.60%
Zura Bio
May 9, 2025
Maintains: Outperform
Price Target: $19 → $17
Current: $3.86
Upside: +340.41%
Corvus Pharmaceuticals
May 9, 2025
Reiterates: Outperform
Price Target: $15 → $17
Current: $7.70
Upside: +120.78%
Immunocore Holdings
May 8, 2025
Maintains: Outperform
Price Target: $85 → $86
Current: $33.99
Upside: +153.02%
Jan 24, 2025
Maintains: Outperform
Price Target: $28 → $18
Current: $7.44
Upside: +141.94%
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $3.52
Upside: -
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $2.94
Upside: +444.22%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $1.79
Upside: +2,421.01%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $17.11
Upside: -
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.28
Upside: -
May 23, 2023
Downgrades: Perform
Price Target: n/a
Current: $6.03
Upside: -
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.51
Upside: +893.38%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $0.48
Upside: +15,515.24%
Nov 17, 2022
Maintains: Outperform
Price Target: $1,600 → $1,100
Current: $6.63
Upside: +16,491.25%